Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs
Authors:
Open Access
- 13 May 2022
- journal article
- research article
- Published by Elsevier in NeuroToxicology
- Vol. 91, 166-176
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Parkinsonforeningen
- Innovationsfonden
- Lundbeck Foundation (R211-2015-3784)
This publication has 56 references indexed in Scilit:
- In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrationsNuclear Medicine and Biology, 2010
- Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal MicrodialysisJournal of Neuroscience, 2008
- Dopamine modulating drugs influence striatal (+)‐[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentrationSynapse, 2008
- A model of MPTP-induced Parkinson's disease in the goldfishNature Protocols, 2007
- A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recoveryBrain, 2007
- Dyskinesia after fetal cell transplantation for parkinsonism: A PET studyAnnals of Neurology, 2002
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transportersNuclear Medicine and Biology, 1996
- Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeysBrain Research, 1990
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+Biochemical and Biophysical Research Communications, 1986